CAPTRUST Financial Advisors
CLRB icon

CAPTRUST Financial Advisors’s Cellectar Biosciences CLRB Stock Holding History

CAPTRUST Financial Advisors’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-7
Closed -$1K – 2423
2022
Q2 		$1K Hold
7
– – ﹤0.01% 4648
2022
Q1 		$1K Hold
7
– – ﹤0.01% 4667
2021
Q4 		$1K Hold
7
– – ﹤0.01% 4549
2021
Q3 		$2K Hold
7
– – ﹤0.01% 4241
2021
Q2 		$2K Hold
7
– – ﹤0.01% 4153
2021
Q1 		$3K Hold
7
– – ﹤0.01% 3898
2020
Q4 		$4K Buy
+7
New +$3.22K ﹤0.01% 2897

Other funds holding CLRB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $127M AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CAPTRUST Financial Advisors's CLRB Position: Q3 2022 in Review

CAPTRUST Financial Advisors sold out of Cellectar Biosciences (CLRB) in Q3 2022, closing a stake of 7 shares — an estimated $1K sold.

CAPTRUST Financial Advisors first reported a position in CLRB in Q4 2020 and held it in 7 quarters. The position peaked at $4K in Q4 2020. 20 funds tracked by Wall St. Rank hold CLRB as of Q3 2022.

  • CAPTRUST Financial Advisors reported no remaining Cellectar Biosciences position as of Q3 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 7 Cellectar Biosciences shares in Q3 2022, an estimated $1K.
  • CAPTRUST Financial Advisors first reported a position in Cellectar Biosciences in Q4 2020 and held it in 7 quarters.
  • CAPTRUST Financial Advisors's Cellectar Biosciences position peaked at $4K in Q4 2020.
  • 20 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q3 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2022, filed 16 Nov 2022.